Highlights 

  • Updated TEM-GBM data show-maintained survival trends more than seven months after the prior analysis. 
  • Eighteen-month survival improved to 44%, up from 38% reported in April 2025. 
  • A patient has reached three years of survival without additional therapeutic interventions until recent progression. 
  • Early immune findings indicate targeted payload delivery by myeloid cells inside the tumor microenvironment. 
  • Genenta ends early November with approx. USD 30 million in cash and short-term investments. 

Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company advancing a cell-based platform for the targeted delivery of therapeutic payloads in oncology, has released new data from its ongoing TEM-GBM study in newly diagnosed glioblastoma multiforme patients with an unmethylated MGMT promoter. As of the November 21, 2025 data cut, 25 patients have been treated with the company’s lead candidate, Temferon. 

The update, arriving more than seven months after the previous cut, shows that key survival indicators have remained consistent and continue to suggest potential clinical promises. Eighteen-month survival has risen to 44%, compared with 38% reported in April. The two-year survival rate stands at 29%, in line with prior findings. Median overall survival remains at 17 months. Historically, uMGMT patients treated with standard therapies show two-year survival of roughly 14% and median survival between 13 and 15 months, highlighting an encouraging comparison for the Temferon-treated cohort. 

Notably, the trial includes the first patient to reach three years of survival following Temferon administration. This individual did not receive any additional therapeutic interventions or second-line treatments during that period. Imaging the three-year mark showed disease progression, leading to a second surgery, yet the patient remains in follow-up. Another patient in the study has also gone for more than three years without further therapeutic intervention. Genenta notes that these observations are descriptive and arise within a disease known for highly variable clinical courses. 

Immune Insights Support Platform’s Tumor-Targeted Mechanism 

The TEM-GBM trial provides the first clinical setting to evaluate Genenta’s platform, which harnesses bone-marrow-derived myeloid cells to transport immune-therapeutic payloads directly into the tumor microenvironment. Early immune observations suggest that these modified cells can indeed migrate to the tumor site and deliver their payloads as designed. 

Although exploratory, these insights help validate the intended mechanism and support the broader development of Temferon. They may also influence future combination strategies and refinements of the underlying cell-based delivery technology, including applications in other hard-to-treat cancers. 

Financial Position Strengthened by Recent Capital Raise 

Genenta also confirmed that, following the closing of its October 27 registered direct offering, the company held approximately USD 30 million in cash and short-term investments as of November 1. This financial position supports ongoing development activities, including the Phase 1/2a metastatic renal cell carcinoma study, which incorporates a combination approach with immune checkpoint inhibitors. 

Temferon is designed as a one-time monotherapy, with additional potential to enhance the effectiveness of approved therapies when used in combination. 

Conclusion 

Genenta’s latest update reinforces the potential of Temferon as a targeted, cell-based therapy for newly diagnosed GBM patients with an unmethylated MGMT promoter. Stable survival indicators, the emergence of multi-year survivors, and early immune data collectively suggest a promising therapeutic profile. With continued clinical progress and strengthened financial resources, Genenta appears positioned to advance its innovative platform across multiple oncology indications. 

Genenta Sciences’ shares closed at USD 1.68, marking a 3.45% decrease from the prior session. 

Also read - Veeva Systems (NYSE:VEEV) Reports 16% Q3 Revenue Growth as Cloud Demand Expands